Immune response to rabies post-exposure prophylaxis in patients with non-HIV secondary immunodeficiencies |
| |
| Institution: | 1. Institut Pasteur, Unit Lyssavirus Epidemiology and Neuropathology, National Reference Centre for Rabies, WHO Collaborating Centre for Research on Rabies, Paris, France;2. Institut Pasteur, Centre Médical, Centre d''Infectiologie Necker-Pasteur, Paris, France;3. Centre Anti Rabique, Service de maladies Infectieuses et Tropicales, CHU Hôtel Dieu, Nantes, France;1. Genomic Research Laboratory, Division of Infectious Diseases, University Hospitals and University of Geneva, Geneva, Switzerland;2. Swiss National Reference Center for Meningococci (www.meningo.ch), Bacteriology Laboratory, Geneva University Hospitals, Geneva, Switzerland;3. Invasive Bacterial Infection and National Reference Centre for Meningococci, Institut Pasteur, Paris, France;1. World Health Organization Regional Office for Europe, UN City, Marmorvej 51, 2100 Copenhagen, Denmark;2. USA Centers for Disease Control and Prevention, 1600 Clifton Rd, MS H24-2, Atlanta, GA 30329, USA;3. World Health Organization Headquarters, Avenue Appia 20, 1211 Geneva, Switzerland;1. Centre for Infectious Diseases, Military Hospital Queen Astrid, Rue Bruyn 1, 1120 Neder-Over-Heembeek, Belgium;2. Department of Clinical Sciences, Institute of Tropical Medicine, Nationalestraat 155, 2000 Antwerp, Belgium;3. Center for the Evaluation of Vaccination, University of Antwerp, 2000 Antwerp, Belgium;1. Trudeau Institute, Inc., Saranac Lake, NY, USA;2. Infectious Disease Research Institute, Seattle, WA, USA;3. University of Connecticut School of Medicine, Department of Immunology and Center on Aging, Farmington, CT, USA;1. Department of Family Medicine, University of Pittsburgh, Pittsburgh, PA, USA;2. Department of Pediatrics, University of Pittsburgh, Pittsburgh, PA, USA;3. Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA;4. National Center Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta GA, USA |
| |
| Abstract: | BackgroundThis study sought to determine the proportion of individuals with non-HIV secondary immunodeficiencies presenting inadequate antibody titers after rabies post-exposure prophylaxis (PEP) and to identify variables associated with inadequate response.MethodsA retrospective review of the records of immunocompromised patients having received a full course of PEP after a rabies exposure and having been tested for post-PPE antibody titers in two French Antirabies Clinics, between 2013 and 2018, was conducted. Antibody titers < 0.5 EU/ml (ELISA) were classified as inadequate.ResultsA total of 28 individuals were included, 6 had inadequate post-PPE titers. None of the tested variable was independently associated with inadequate titers.ConclusionsInadequate response was unpredictable and not explained either by the characteristics of patients or by the PEP regimen they received. These findings support the WHO recommendation to systematically assess post-PEP response in immunocompromised patients to detect non-responders, who might require an additional dose. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
